Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Capital Expenditures for 8 consecutive years, with $434000.0 as the latest value for Q1 2026.

  • For Q1 2026, Capital Expenditures fell 7.07% year-over-year to $434000.0; the TTM value through Mar 2026 reached $1.4 million, down 76.01%, while the annual FY2025 figure was $1.4 million, 88.71% down from the prior year.
  • Capital Expenditures hit $434000.0 in Q1 2026 for Kymera Therapeutics, up from $106000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $11.6 million in Q4 2023 and bottomed at -$189000.0 in Q3 2024.
  • Average Capital Expenditures over 5 years is $3.1 million, with a median of $735000.0 recorded in 2022.
  • Year-over-year, Capital Expenditures surged 3016.62% in 2023 and then plummeted 102.34% in 2024.
  • Kymera Therapeutics' Capital Expenditures stood at $373000.0 in 2022, then soared by 3016.62% to $11.6 million in 2023, then tumbled by 91.95% to $936000.0 in 2024, then tumbled by 88.68% to $106000.0 in 2025, then skyrocketed by 309.43% to $434000.0 in 2026.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $434000.0, $106000.0, and $181000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.